Patents by Inventor Brian Jay Druker
Brian Jay Druker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110129852Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.Type: ApplicationFiled: July 12, 2010Publication date: June 2, 2011Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Müller, Oliver Gerhard Ottmann, Markus Warmuth
-
Publication number: 20100021920Abstract: The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production ofType: ApplicationFiled: August 21, 2009Publication date: January 28, 2010Inventors: Christophe Barthe, Susan Branford, Amie Corbin, Brian Jay Druker, Justus Duyster, Andreas Hochhaus, Timothy Hughes, Sebastian Kreil, Thlbaut Leguay, Francois-Xavier Mahon, Gèrald Marit, Martin Müller, Christian Peschel, Claude Preudhomme, Catherine Roche Lestienne, Zbigniew Rudzki
-
Publication number: 20100021921Abstract: The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production ofType: ApplicationFiled: August 21, 2009Publication date: January 28, 2010Inventors: Christophe Barthe, Susan Branford, Amie Corbin, Brian Jay Druker, Justus Duyster, Andreas Hochhaus, Timothy Hughes, Sebastian Kreil, Thibaut Leguay, Francois-Xavier Mahon, Gerald Marit, Martin Muller, Christian Peschel, Claude Preudhomme, Catherine Roche Lestienne, Zbigniew Rudzki
-
Publication number: 20090191606Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1 -ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.Type: ApplicationFiled: December 17, 2008Publication date: July 30, 2009Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Muller, Oliver Gerhard Ottmann, Markus Warmuth
-
Publication number: 20090117641Abstract: The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production ofType: ApplicationFiled: June 30, 2008Publication date: May 7, 2009Inventors: Christophe Barthe, Susan Bradford, Amie Corbin, Brian Jay Druker, Justus Duyster, Andreas Hochhaus, Timothy Hughes, Sebastian Kreil, Thibaut Leguay, Francios-Xavier Mahon, Gerald Marit, Martin Muller, Christian Peschel, Claude Preudhomme, Catherine Roche Lestienne, Zbigniew Rudzki
-
Patent number: 6958335Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.Type: GrantFiled: October 26, 2001Date of Patent: October 25, 2005Assignees: Novartis AG, Dana-Farber Cancer Institute, Inc., Oregon Health & Science UniversityInventors: Elisabeth Buchdunger, Renaud Capdeville, George Daniel Demetri, Sasa Dimitrijevic, Brian Jay Druker, Jonathan A. Fletcher, Michael C. Heinrich, Heikki Joensuu, Sandra Leta Silberman, David Tuveson
-
Publication number: 20040023976Abstract: 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula (I) or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.Type: ApplicationFiled: August 11, 2003Publication date: February 5, 2004Inventors: Elisabeth Buchdunger, Renaud Capdeville, George Daniel Demetri, Sasa Dimitrijevic, Brian Jay Druker, Jonathan A. Fletcher, Michael C. Heinrich, Heikki Joensuu, Sandra Leta Silberman, David Tuveson
-
Publication number: 20030170851Abstract: The present invention relates to isolated polypeptides which comprise an amino acid sequence consisting of a mutated functional Abl kinase domain, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides.Type: ApplicationFiled: October 3, 2002Publication date: September 11, 2003Inventors: Christophe Barthe, Pascale Cony-Makhoul, Amie Corbin, Sven De Vos, Brian Jay Druker, Harald Gschaidmeier, Michael Hallek, Andreas Hochhaus, Dieter Hoelzer, Wolf-Karsten Hofmann, Phillip Koeffler, Sebastian Kreil, Francois-Xavier Mahon, Martin Muller, Oliver Gerhard Ottmann, Markus Warmuth